GI
NTLA icon

Gradient Investments’s Intellia Therapeutics NTLA Stock Holding History

Gradient Investments’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-162
Closed -$2K – 1152
2020
Q1 		$2K Buy
+162
New +$2.18K ﹤0.01% 930

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Gradient Investments's NTLA Position: Q2 2020 in Review

Gradient Investments sold out of Intellia Therapeutics (NTLA) in Q2 2020, closing a stake of 162 shares — an estimated $2K sold.

Gradient Investments first reported a position in NTLA in Q1 2020 and held it in 1 quarter. The position peaked at $2K in Q1 2020. 164 funds tracked by Wall St. Rank hold NTLA as of Q2 2020.

  • Gradient Investments reported no remaining Intellia Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Gradient Investments sold 162 Intellia Therapeutics shares in Q2 2020, an estimated $2K.
  • Gradient Investments first reported a position in Intellia Therapeutics in Q1 2020 and held it in 1 quarter.
  • Gradient Investments's Intellia Therapeutics position peaked at $2K in Q1 2020.
  • 164 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2020.

Based on Gradient Investments's 13F filing for Q2 2020, filed 10 Jul 2020.